Good evening, ladies and gentlemen, and welcome to Verrica Pharmaceuticals' third-quarter 2026 corporate update conference call. At this time, all participants are in listen-only mode. After the speaker's remarks, there will be a question-and-answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference. Verrica Pharmaceuticals (NasdaqGM:VRCA) Q3 2026 Earnings call November 12, 2026 04:30 PM ET Co ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q3 2026 Earnings call November 12, 2026 04:30 PM ET Speaker0Good evening, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Third Quarter 2026 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question-and-answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your c ...

– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million – – Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline data for each trial expected in Q1 2027 and mid-2027, respectively – – Company achieved pre-defined revenue, growth and operational milestones under credit facility to unlock full access to $27.5 million of non-dilu ...